JPWO2020219959A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020219959A5
JPWO2020219959A5 JP2021563185A JP2021563185A JPWO2020219959A5 JP WO2020219959 A5 JPWO2020219959 A5 JP WO2020219959A5 JP 2021563185 A JP2021563185 A JP 2021563185A JP 2021563185 A JP2021563185 A JP 2021563185A JP WO2020219959 A5 JPWO2020219959 A5 JP WO2020219959A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
cells
pharmaceutical composition
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563185A
Other languages
English (en)
Japanese (ja)
Other versions
JP7650819B2 (ja
JP2022530089A (ja
JP2022530089A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029929 external-priority patent/WO2020219959A1/en
Publication of JP2022530089A publication Critical patent/JP2022530089A/ja
Publication of JPWO2020219959A5 publication Critical patent/JPWO2020219959A5/ja
Publication of JP2022530089A5 publication Critical patent/JP2022530089A5/ja
Application granted granted Critical
Publication of JP7650819B2 publication Critical patent/JP7650819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2021563185A 2019-04-24 2020-04-24 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用 Active JP7650819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838280P 2019-04-24 2019-04-24
US62/838,280 2019-04-24
PCT/US2020/029929 WO2020219959A1 (en) 2019-04-24 2020-04-24 Anti-cd45 antibody drug conjugates and uses thereof

Publications (4)

Publication Number Publication Date
JP2022530089A JP2022530089A (ja) 2022-06-27
JPWO2020219959A5 true JPWO2020219959A5 (https=) 2023-05-08
JP2022530089A5 JP2022530089A5 (https=) 2023-05-08
JP7650819B2 JP7650819B2 (ja) 2025-03-25

Family

ID=72940686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563185A Active JP7650819B2 (ja) 2019-04-24 2020-04-24 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用

Country Status (4)

Country Link
US (1) US20220175951A1 (https=)
EP (1) EP3958910A4 (https=)
JP (1) JP7650819B2 (https=)
WO (1) WO2020219959A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
KR102526802B1 (ko) 2016-05-11 2023-05-02 소니그룹주식회사 초고명도 이량체성 또는 중합체성 염료
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
CN111093711A (zh) 2017-10-05 2020-05-01 索尼公司 可编程的树枝状药物
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
US12194104B2 (en) 2018-01-12 2025-01-14 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
EP3737419B1 (en) 2018-01-12 2024-04-10 Sony Group Corporation Phosphoalkyl polymers comprising biologically active compounds
US11874280B2 (en) 2018-03-19 2024-01-16 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
US12006438B2 (en) 2018-06-27 2024-06-11 Sony Group Corporation Polymeric dyes with linker groups comprising deoxyribose
EP3820944A1 (en) 2018-07-13 2021-05-19 Sony Corporation Polymeric dyes having a backbone comprising organophosphate units
JP2022512781A (ja) * 2018-10-30 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド 同種造血幹細胞移植の方法
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
WO2022125564A1 (en) 2020-12-07 2022-06-16 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
EP4408477A1 (en) * 2021-09-30 2024-08-07 Sony Group Corporation Pyrrolobenzodiazepine conjugates for cancer treatment
WO2023183927A2 (en) 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
JP2026500540A (ja) 2022-12-23 2026-01-07 シメイオ セラピューティクス アーゲー Ｃｄ４５を標的とする抗体
CN120554513B (zh) * 2025-07-28 2025-11-21 杭州华大生命科学研究院 一种抗cd45抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
HUE071169T2 (hu) * 2016-03-07 2025-08-28 Actinium Pharmaceuticals Inc Stabilizált, radioaktívan jelölt anti-CD45 immunglobulin-készítmények
CN109641051A (zh) * 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
CA3117367A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
JP7650819B2 (ja) 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用
JP7709376B2 (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
JP2025060760A (ja) アマトキシン抗体薬物複合体及びその使用
JPWO2020219959A5 (https=)
CN113302203A (zh) 抗cd45抗体及其缀合物
US20220175944A1 (en) Anti-cd117 antibody-drug conjugates and uses thereof
KR20210086683A (ko) 동종이형 조혈 줄기 세포 이식 방법
US20240075157A1 (en) Fc silenced antibody drug conjugates (adcs) and uses thereof
KR20220091567A (ko) 항-cd45 항체 및 이의 컨쥬게이트
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
JP2022530443A5 (https=)
US20220226493A1 (en) Anthracycline antibody-drug conjugates and uses thereof
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
JPWO2020219775A5 (https=)
KR20220154676A (ko) 동종 이식을 위한 조성물 및 방법
JPWO2020219778A5 (https=)
JPWO2020219774A5 (https=)
RU2826004C2 (ru) Аматоксиновые конъюгаты антитела с лекарственным средством и их применение